GIP and GLP-1 receptor co-agonist
Tirzepatide 10 mg subcutaneous once weekly
TIRZ_SC_10MG_QW
Related
- All doses pooled: Tirzepatide injection
- Tirzepatide 1 mg subcutaneous once weekly
- Tirzepatide 5 mg subcutaneous once weekly
- Tirzepatide 15 mg subcutaneous once weekly
- Tirzepatide maximum tolerated dose injection once weekly
- Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg
- Tirzepatide 12 mg injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.78 (-2.11 to -1.45) | 0.96 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.42 (-0.96 to 0.13) | 0.71 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -2.13 (-2.61 to -1.54) | 0.90 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.59 (-1.96 to -1.10) | 0.85 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.86 (-2.67 to -0.58) | 0.78 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -7.73 (-9.81 to -5.66) | 0.94 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -9.00 (-11.73 to -5.35) | 0.93 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -5.98 (-10.20 to -1.11) | 0.81 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -10.09 (-12.24 to -7.24) | 0.85 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -6.85 (-10.98 to -1.04) | 0.78 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 49.78 (10.26 to 192) | 0.98 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 42.44 (2.33 to 211) | 0.90 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.46 (0.05 to 4.28) | 0.47 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.20 (1.31 to 8.32) | 0.38 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.43 (0.14 to 1.24) | 0.71 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.57 (-7.30 to 2.15) | 0.55 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.13 (-7.06 to 0.81) | 0.91 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 49.28 (11.14 to 220) | 0.97 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 19.01 (4.08 to 94.30) | 0.89 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.78 (0.60 to 1.03) | 0.63 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.55 (1.00 to 2.49) | 0.51 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.19 (2.35 to 4.35) | 0.43 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.99 (1.96 to 4.49) | 0.47 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.02 (2.30 to 4.00) | 0.21 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.24 (2.03 to 5.26) | 0.23 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.66 (0.05 to 7.41) | 0.53 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.69 (0.01 to 56.73) | 0.56 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -18.37 (-24.06 to -8.12) | 0.70 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -6.17 (-10.38 to -1.91) | 0.36 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 20.28 (5.12 to 72.05) | 0.60 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 3.54 (0.94 to 13.51) | 0.34 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.89 (0.67 to 14.78) | 0.29 |
| Overweight or obesity without diabetes (adults) | Weight loss of 20 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 5.23 (0.73 to 59.09) | 0.43 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.95 (-6.22 to 9.84) | 0.49 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.99 (0.51 to 1.77) | 0.56 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.63 (3.36 to 6.51) | 0.34 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.94 (3.44 to 10.33) | 0.37 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.52 (2.28 to 5.59) | 0.22 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.73 (2.06 to 6.92) | 0.24 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Serious adverse events | longest follow-up | Placebo | HR 1.46 (0.27 to 8.20) | 0.42 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.11 (0.00 to 1.75) | 0.95 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Nausea | longest follow-up | Placebo | HR 2.71 (0.82 to 8.75) | 0.57 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Vomiting | longest follow-up | Placebo | HR 1.91 (0.25 to 14.21) | 0.75 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Diarrhea | longest follow-up | Placebo | HR 1.68 (0.55 to 4.92) | 0.48 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Constipation | longest follow-up | Placebo | HR 2.70 (0.64 to 11.24) | 0.35 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.16 (0.00 to 3.31) | 0.92 |
Trials
- SURMOUNT-CNEfficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)2021 · 210 randomized · 52 weeks
- NCT04311411Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI2020 · 114 randomized · 6 weeks
- NCT04235959A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide2020 · 24 randomized · 24 weeks
- SURPASS-6A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)2020 · 1,428 randomized · 52 weeks
- SURMOUNT-1Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)2019 · 2,539 randomized · 72 weeks
- SURPASS-3A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes2019 · 1,444 randomized · 52 weeks
- SYNERGY-NASHA Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)2019 · 190 randomized · 52 weeks
- SURPASS-1A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone2019 · 478 randomized · 40 weeks
- NCT04093752A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea2019 · 917 randomized · 40 weeks
- SURPASS-5Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin2019 · 475 randomized · 40 weeks
- NCT03861039A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)2019 · 443 randomized · 52 weeks
- SURPASS-4Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)2018 · 2,002 randomized · 104 weeks
- NCT03322631A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY32981762017 · 48 randomized · 8 weeks
- NCT03131687A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus2017 · 318 randomized · 26 weeks